Responses
Clinical/translational cancer immunotherapy
Original research
Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma
Compose a Response to This Article
Other responses
No responses have been published for this article.
